Health Evidence Network synthesis report 53
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
LEAVING NO-ONE BEHIND | “A Journey to End NTDs – Elimination and Care” records what we have achieved over the last year and where we are now. It presents our plan of action for the coming years, bringing our ‘traditional’ NTD work together with ‘Disease Management Disability and Inclusio...n’ (DMDI), Community Based Inclusive Development (CBID) and Livelihoods. We care for those affected and we’re working to enhance community and government ownership through national
health system strengthening, community engagement and cross-sectoral action. Ultimately, we are working to free future generations from these menacing diseases, improving prevention and treatment, without forgetting those for whom prevention and treatment are too late because they already have a disability.
more
Tackling Tuberculosis in Under-Served Populations: A Resource for TB Control Boards and their partners
3rd Edition – July 2017
www.msfaccess.org
L’OMS a ciblé 17 maladies comme des Maladies Tropicales Négligées. Ces maladies sont très différentes les unes des autres, mais elles ont comme point commun de toucher principalement les populations les plus pauvres. Elles maintiennent dans la pauvreté les populations ayant initialement un n...iveau de développement faible. Ces maladies coexistent au sein des mêmes populations, augmentant de ce fait leur vulnérabilité.
more
Un análisis desde la perspectiva del sector de la salud en América Latina y el Caribe
Washington, D.C., 2017
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Technical Update
HIV Treatment
July 2017
Lessons from the STEP-TB Project.
Accessed November 2017.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more